Abstract:In recent years, immunotherapy has achieved significant success in the treatment of a variety of cancer types, including melanoma, non-small cell lung cancer, and colorectal cancer. However, in stark contrast, patients with glioblastoma (GBM) show remarkably poor responses to immunotherapy, failing to derive any therapeutic benefit. Thus, an understanding of the immunosuppressive microenvironment of GBM, which is considered an immunotherapy-cold tumor, is of paramount importance. One common and distinctive genetic mutation found in gliomas is that of EGFRvIII, which is linked with enhanced cell proliferation, invasion, migration, and angiogenesis in GBM. Intriguingly, we found that this mutation induced a significantly more severe immunosuppressive microenvironment compared with wild-type EGFR. To unravel the mechanisms underlying EGFRvIII mutation-induced immunosuppression in GBM, we posited that the mutant variant secretes an array of immunosuppression-related proteins into the glioma microenvironment. To investigate this, we conducted proteomic analysis of conditioned media from EGFRvIII mutant cell lines and discovered significant changes in the expression of insulin-like growth factor-binding protein-2 (IGFBP2), a well-documented oncogenic protein. Although IGFBP2 is known to be upregulated in various tumor types and is associated with malignant behaviors such as proliferation and invasion in gliomas, its role in glioma immunology remains largely unexplored. In line with our earlier bioinformatic analyses, our study revealed significant enrichment of IGFBP2 in pathways related to immunosuppression in GBM. Thus, in the present investigation, we analyzed the mechanisms by which IGFBP2 induces an immunosuppressive microenvironment. Using co-culture models, we found that IGFBP2-overexpressing glioma cells as well as glioma cells treated with exogenous IGFBP2 recruited immune cells through binding to integrin αvβ5. Furthermore, we demonstrated that IGFBP2 promoted the secretion of the classical macrophage polarization factor IL-10 by phosphorylation of STAT3. These findings indicate the significant influence of IGFBP2 in steering glioma-associated macrophages toward a pro-tumor M2-like phenotype. We also observed that IGFBP2 upregulated the expression of PD-L1 on tumor cell surfaces. These results were verified in animal experiments. Intriguingly, our preliminary data indicated that exogenous IGFBP2 translocated to the cell nucleus within hours, and immunoprecipitation assays confirmed its interaction with STAT3 in vitro. These findings collectively underscore the pivotal role of IGFBP2 in the creation of the immunosuppressive microenvironment induced by EGFRvIII mutation. Consequently, targeting IGFBP2 holds great promise for advancing immunotherapeutic approaches in EGFRvIII-mutant glioblastomas, offering an exciting avenue for potential treatments of GBM. Citation Format: Jikang Fan, Xisen Wang, Tao Li, Xuejun Yang, Wei Zhang. IGFBP2 assists EGFRvIII-positive glioblastoma to evade immune elimination [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 2650.

IGFBP2 promotes immunosuppression associated with its mesenchymal induction and FcγRIIB phosphorylation in glioblastoma

Abstract 2650: IGFBP2 assists EGFRvIII-positive glioblastoma to evade immune elimination

IGFBP2 promotes neural stem cell maintenance and proliferation differentially associated with glioblastoma subtypes

IGFBP5 increases cell invasion and inhibits cell proliferation by EMT and Akt signaling pathway in Glioblastoma multiforme cells

IGFBP3 induces PD-L1 expression to promote glioblastoma immune evasion

IGF2BP2 modulates autophagy and serves as a prognostic marker in glioma

LRIG2 promotes glioblastoma progression by modulating innate antitumor immunity through macrophage infiltration and polarization

Abstract LB-466: Genomic Loss of Microrna 491 Contributes to IGFBP2 Overexpression and Stemness in GBM

IGFBP2 promotes vasculogenic mimicry formation via regulating CD144 and MMP2 expression in glioma

N6-methyladenosine Reader IGF2BP3 As a Prognostic Biomarker Contribute to Malignant Progression of Glioma.

Cancer-associated fibroblast-associated gene IGFBP2 promotes glioma progression through induction of M2 macrophage polarization

Comprehensively Investigating the Expression Levels and the Prognostic Role of Transforming Growth Factor Beta-Induced (TGFBI) in Glioblastoma Multiforme

Immu-72. Type I Interferon Signaling Within Glioblastoma Cells Promotes T-Cell Exhaustion And Resistance To Checkpoint Inhibitors

FOSL2-mediated transcription of ISG20 induces M2 polarization of macrophages and enhances tumorigenic ability of glioblastoma cells

Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth

AB046. Dual Role of POSTN in Maintaining Glioblastoma Stem Cells and Immune- Suppressive Microglia in Glioblastoma

Impact of Beta-2 Microglobulin Expression on the Survival of Glioma Patients Via Modulating the Tumor Immune Microenvironment.

β2-microglobulin maintains glioblastoma stem cells and induces M2-like polarization of tumor-associated macrophages

IKBKE, a Prognostic Factor Preferentially Expressed in Mesenchymal Glioblastoma, Modulates Tumoral Immunosuppression Through the STAT3/PD‐L1 Pathway

Abstract B009: GBM cells mimic regulatory T cell function to protect the CSC pool from immune surveillance in recurrent GBM

Reversing Epigenetic Gene Silencing to Overcome Immune Evasion in CNS Malignancies